Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients
Cattin S, Fellay B, Pradervand S, Trojan A, Ruhstaller T, Rüegg C, Fürstenberger G. Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. Oncotarget 2016; 7:11137-50.
08.03.2016
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients
08.03.2016
Oncotarget 2016; 7:11137-50
Cattin Sarah, Fellay Benoît, Pradervand Sylvain, Trojan Andreas, Ruhstaller Thomas, Rüegg Curzio, Fürstenberger Gregor
Weiter
